⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 30, 2024International Journal of Clinical Pharmacology and TherapeuticsOpen Access

Adequate IVIG dosing is associated with an improved long-term outcome in secondary immunodeficiency: A prospective, non-interventional study

Artur Bauhofer Ümniye Balaban Sonja Schimo Monika Mayer Jörg Schüttrumpf Stephan Borte

View Full Paper

Ask AI

Bookmark

Share

Abstract

To assess the safety, tolerability, and effectiveness of the intravenous immunoglobulin (IVIG) Intratect 50 g/L in immunoglobulin replacement therapy (IgRT) in a prospective, large-scale non-interventional study (NIS). The analysis focused upon patients with secondary immunodeficiency (SID), the most frequent indication for IgRT in this NIS.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bauhofer et al. (2024) studied this question.

synapsesocial.com/papers/68e5e80fb6db64358757d04a https://doi.org/10.5414/cp204595

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Novel intravenous human IVIG in patients with secondary immunodeficiency: Interim analysis of a multicenter, prospective, non-interventional studyHuman Clinical Trial · 2026
2Incidence of severe infections in patients with multiple myeloma treated with immunoglobulin-replacement therapy2025
3Evaluation of IVIG for Prevention of Infections Occurring On-study and Treatment of Infection of Solid Organ Recipients With Secondary Antibody Deficiency: A Phase 2 Randomized Clinical TrialRCT · 2026 · 2 citations
4Safety and tolerability of a new intravenous immunoglobulin 10% in patients with primary immunodeficiencyLate-Phase Clinical Trial · 2026
5Intravenous Immunoglobulin 10% in Children with Primary Immunodeficiency DiseasesCohort Study · 2018 · 11 citations